Meet Our Speakers!
We have an amazing agenda of panelists. Here you can find their full bios and websites.
Robert Galvin
MD
Dr. Robert Galvin is the Chief Executive Officer of Equity Healthcare (EH), which oversees the management of health care for firms owned by private equity companies. The focus is on using purchasing power to create innovative ways to achieve higher value health care, through improved population health, clinical quality and delivery system reforms. Currently, EH encompasses over 30 companies with healthcare spending exceeding $1.5B annually.
Before joining Blackstone as a Senior Advisor, Dr. Galvin was Executive Director of Health Services and Chief Medical Officer for General Electric (GE) for fifteen years, where he was in charge of the design, financial and clinical performance of GE’s health programs. He was also responsible for health policy strategies affecting employees. Dr. Galvin is a nationally recognized leader in the areas of market-based health policy and financing, quality measurement and payment reform.
His work has been widely published in the New England Journal of Medicine and Health Affairs and he was a co-founder of the Leapfrog Group and founder of two other groups, Bridges to Excellence and Catalyzing Payment Reform, all innovative non-profits that have helped drive the quality agenda. Dr. Galvin is a member of the Institute of Medicine and sits on the IOM’s Board on Health Care Services. He is also on the Board of Directors of the National Quality Forum and a member of the National Advisory Council for the Agency for Healthcare Research and Quality (AHRQ). Dr. Galvin is Professor Adjunct of Medicine and Health Policy at Yale. His work has received awards from the National Business Group on Health, the Healthcare Financial Management Association and the National Coalition for Cancer Survivorship. He is a fellow of the American College of Physicians.
Brian Anderson
MD
Dr. Brian Anderson is the Chief Executive Officer of the Coalition for Health AI (CHAI), a non-profit coalition he co-founded in 2021. CHAI is focused on developing a set of consensus-driven guidelines and best practices for Responsible AI in Health, as well as supporting the ability to independently test and validate AI for safety and effectiveness.
​
Prior to leading CHAI, Dr. Anderson was the Chief Digital Health Physician at MITRE, where he led research and development efforts across major strategic initiatives in digital health alongside industry partners and the U. S. Government. He was responsible for leading much of MITRE’s work during the COVID-19 pandemic, working closely with the White House COVID Task Force and Operation Warp Speed. He led MITRE’s largest R&D effort in Oncology, focusing on initial development of mCODE and the use of AI in more efficient and inclusive clinical trial design.
​
Dr. Anderson is an internationally recognized author and expert in digital health, and is regularly engaged as a speaker on digital health innovation, health standards development, clinical decision support systems, and interoperability.​ Prior to MITRE, Anderson led the Informatics and Network Medicine Division at athenahealth. He has also served on several national, and international, health information technology committees in partnership with the Office of the National Coordinator (ONC), the National Institutes of Health (NIH) and the Organization for Economic Cooperation and Development (OECD).
Harlan Krumholz
MD
Harlan Krumholz is a cardiologist and scientist at Yale University and Yale New Haven Hospital. He is the Harold H. Hines, Jr. Professor of Medicine. He is a leading expert in the science to improve the quality and efficiency of care, eliminate disparities and promote equity, improve integrity and transparency in medical research, engage patients in their care, and avoid wasteful practices. Recent efforts are focused on harnessing the digital transformation in healthcare to accelerate knowledge generation and facilitate the delivery of care aligned with each patient’s needs and preferences.
​
Dr. Krumholz is director of the Yale New Haven Hospital Center for Outcomes Research and Evaluation (CORE), an organization dedicated to improving health and health care through research, tools, and practices that produce discovery, heighten accountability, and promote better public health and clinical care. He co-founded and co-leads the Yale University Open Data Access (YODA) Project, designed to increase access to clinical research data and promote their use to generate new knowledge. He also co-founded and co-leads medRxiv, a non-profit preprint server for the medical and health sciences. He was a founding faculty co-director of the Yale Center for Research Computing.
​
Dr. Krumholz has been honored by membership in the National Academy of Medicine, the Association of American Physicians, and the American Society for Clinical Investigation. He was named a Distinguished Scientist of the American Heart Association and received their Award of Meritorious Achievement and Clinical Research Prize. He served as a member of the Advisory Committee to the Director of the National Institutes of Health. Dr. Krumholz received the Friendship Award from the People’s Republic of China in recognition of his collaborative efforts to develop a national cardiovascular research network and was named by the Chinese Society of Cardiology as a Top-10 Distinguished International Cardiologist for his contributions to the development of cardiovascular medicine in China. He founded the American Heart Association’s Quality of Care and Outcomes Research Council and co-founded their annual conference. He was the founding editor of Circulation: Cardiovascular Quality and Outcomes; founding editor of CardioExchange, a social media site of the publisher of the New England Journal of Medicine; and editor of Journal Watch Cardiology of the New England Journal of Medicine. He was a founding Governor of the Patient-Centered Outcomes Research Institute. He is the Editor-in-Chief of JACC, a pre-eminent cardiovascular medical journal.
​
He co-founded HugoHealth, a patient-centric platform that engages people as partners in research and clinical care, facilitates the secure acquisition and movement of digital health data, and promotes learning health communities. He also co-founded Refactor Health, an enterprise healthcare AI-augmented health data management company.
Before joining the Yale faculty in 1992, Dr. Krumholz received a BS (Biology) from Yale, an MD from Harvard Medical School, and a Masters in Health Policy and Management (SM) from the Harvard University School of Public Health. At Yale, he directed the Robert Wood Johnson Foundation Clinical Scholars Program from 1996-2017 and serves as Director Emeritus of the Yale National Clinician Scholars Program. Dr. Krumholz has published over 1500 articles and three books with an h-index of more than 240.
Jennifer Miller
PhD
Jennifer E. Miller, PhD, is Co-Director of the Program for Biomedical Ethics and an Associate Professor in Yale School of Medicine. She is also the Director of the Good Pharma Scorecard (an index that ranks and rates pharmaceutical companies on their bioethical performance) and Founder of the nonprofit Bioethics International.
​
Her current research focuses on ethics, equity and governance in drug, vaccine, and medical device research, development, and accessibility as well as in the ethics of healthcare data sharing. She also specializes in developing and using metrics to enhance accountability and social responsibility in biomedical innovation.
​
Prior to joining Yale’s faculty, she was an Assistant Professor (tenure track) in NYU School of Medicine and completed training in physics, regulatory governance, bioethics, and ethics at Fordham University, Duke University, Regina Apostolorum Pontifical University, and Harvard University.
Amber Childs
PhD
Dr. Amber W. Childs is an award-winning, nationally renowned child and adolescent clinical expert, innovator, and transformational leader. As a licensed clinical psychologist, she brings nearly 15 years of deep experience improving equity, access, and mental health outcomes for youth through data-driven quality improvement and cuttIng-edge digital delivery. Dr. Childs is currently an Associate professor of psychiatry in the Yale School of Medicine, and is a member of the medical staff at Yale New Haven Psychiatric Hospital (YNHPH). Additionally, Dr. Childs is the co-founder and director of the Getting Racism Out of our Work (GROW) initiative at Yale, co-founder of the Yale Measurement-Based Care Collaborative and founder of M-Select, a comprehensive digital mental health solution for youth. Her transformational leadership roles have included Director of Training for the Yale Doctoral Internship in Clinical and Community Psychology in the School of Medicine and Co-Director of the Division of Quality and Innovation within YNPHP, and Chief Clinical Officer at BeMe Health.
Dr. Childs is a respected and frequent contributor to the peer-reviewed literature with scores of published manuscripts and presentations to her name. She has also held numerous national advisory board and appointed ambassadorship roles, including the Measurement-Based Care Advisory board for the American Psychological Association where she was an elected advisor serving for 4 years. Most recently, she was appointed as an Ambassador for the American Academy of Pediatrics Center for Social Media and Youth Mental Health. Childs is also a sought aWer subject maYer expert and presenter, with her thought leadership has been featured in The New York Times, The Washington Post, CNBC, Yale Medicine Magazine, The Har[ord Courant and more.
​
Dr. Childs earned her PhD in clinical psychology from the University of Tennessee, Knoxville and completed a doctoral internship and postdoctoral residency at the Institute of Living/Har[ord Hospital, where she specialized in child and adolescent services. She resides in Connecticut with her husband and two children.
Shirley Wang
PhD
Shirley Wang is an Assistant Professor in the Department of Psychology at Yale University, where she directs the Computational Clinical Science Lab (CCSL). Shirley’s research aims to develop and harness methods that can capture and model the immense complexity of psychopathology, with a focus on suicide, nonsuicidal self-injury, and eating disorders. Her work integrates methods from across the clinical and computational sciences, including machine learning, mathematical modeling, real-time monitoring (e.g., via smartphones and wearable biosensors). Her work has been funded by the National Institutes of Health, the National Science Foundation, several private foundations, and published in over 50 scientific papers and book chapters. Shirley’s research and mentorship has also been recognized through the receipt of several awards, and she was recently listed as one of Forbes’ 30 Under 30 in Healthcare.
Seth Feuerstein
MD, JD
Seth Feuerstein, MD, JD, is the Chairman and Co-founder of Vita Health and the Co-founder and Chief Executive Officer of Oui Therapeutics. A psychiatrist by background, Seth has spent the last three decades innovating the healthcare and biomedical sciences and driving change in the healthcare system. Through his combined medical and law degrees, Seth’s focus has been addressing gaps in care and equity in access to quality healthcare.
​
Prior to founding Vita Health and Oui Therapeutics, Seth served as Chief Medical Officer of Medical and Digital at Magellan Health and founded and developed Cobalt Therapeutics, a digital health company and platform to address 90 percent of behavioral health disorders. In addition to his roles at Vita Health and Oui Therapeutics, Seth serves on the clinical faculty at the Yale School of Medicine, on the advisory board of the Yale Center for Biomedical and Interventional Technology, and as a psychiatrist for the Connecticut Department of Mental Health and Addiction Services.
Luis Voloch
Luis Voloch was the cofounding CTO at Immunai (an AI-powered cancer immunotherapy biotech valued at over 1B, based in NYC) until late 2022, building the company to 150 people, raising ~$300M, and forming partnerships with many large pharma companies. He is a Ph.D. dropout from MIT (where he received a best thesis award working in AI) and was a Lecturer at Stanford’s GSB, before founding Jimini Health.
John Morton
MD, MPH, MHA, BS, FACS, FASMBS
Dr. John Morton is the System Lead for Surgical Quality and Bariatric Services in the Yale New Haven Health System and Vice-Chair for Quality, Division Chief for Bariatric and Minimally Invasive Surgery and Professor in the Department of Surgery at the Yale School of Medicine. He served as Chief of Bariatric and Minimally Invasive Surgery, Clinic Chief for the Bariatric and Metabolic Inter-Disciplinary Clinic and Director of Bariatric and Minimally Invasive Surgery Fellowship at Stanford University.
​
Dr. Morton received undergraduate, Masters in Public Health, and Medical Doctor Degrees from Tulane University and a Masters in Health Administration from University of Washington. He was the first surgical resident to receive a Robert Wood Johnson Clinical Scholar Fellowship in the program’s history at University of Washington and completed an advanced laparoscopic surgery fellowship at University of North Carolina, Chapel Hill. He is a Diplomate of both the American Board of Surgery and American Board of Obesity Medicine and certified in Medical Quality by the American College of Medical Quality.​
​
Dr. Morton has the unique distinction of having served as Surgical Quality Director for two Top 20 US News & World Report Honor Roll Hospitals. He is the inaugural national Chair of the Metabolic and Bariatric Surgery Accreditation and Quality Improvement Program (MBSAQIP), a collaboration for 800 hospitals between the American Society of Metabolic and Bariatric Surgery and the American College of Surgeons. He has overseen 3 national standards, establishment of the clinical registry, and 3 national quality improvement projects within MBSAQIP. From 2014-15, he served as elected President of the American Society of Metabolic and Bariatric Surgery (ASMBS). In 2017, he received the highest honor accorded to a bariatric surgeon with the ASMBS Foundation Award for Outstanding Achievement and in 2019 received the Walter Pories Award. He has been recognized as a bariatric surgery leader by Agency for Healthcare Research and Quality, RAND, American College of Surgeons, Who’s Who and America’s Top Surgeons. He was named Castle Connolly’s Physician of the Year for Clinical Excellence in 2012. Dr. Morton ounded the first obesity related Political Action Committee, Obesity PAC on behalf of the American Society for Metabolic and Bariatric Surgery and Chair of the National Obesity Collaborative Care Summit for 35 Different Medical Societies.
Bubu Banini
MD, PhD
Bubu Banini, MD, PhD, specializes in digestive diseases, treating various liver conditions, such as hepatitis A, B, and E, alcoholic cirrhosis, and nonalcoholic fatty liver disease (NAFLD).
​
As the Translational Research Director of the Metabolic Health and Weight Loss Program, Dr. Banini's research interests include NAFLD, decompensated cirrhosis and hepatic hydrothorax, liver cancer, portal hypertension and transient elastography, and the role of genes in alcoholic hepatitis.
​
Dr. Banini has received various awards, including the Young Scientist Travel Award, the Fellow Travel Awards for AASLD, DDW, ACG, and EASL, and the Early Investigator Career Enhancement Program Award.
​
Dr. Banini is an assistant professor of medicine at Yale School of Medicine.
Jorge Moreno
MD
Dr. Jorge O. Moreno is an Assistant Professor of Medicine at Yale School of Medicine. Previously, he worked in a community practice in Branford, CT and quickly became a highly sought-after internist. From an early age, Dr. Moreno knew he wanted to work in primary care to treat and help prevent disease as well as foster lasting relationships with patients.
​
Dr. Moreno is originally from Mexico and is also fluent in Spanish. He grew up in New Rochelle, NY and completed his undergraduate degree at Columbia University in 2006. He later worked for HealthCorps, an organization teaching high school student about leading a healthier lifestyle. In 2011, he obtained his medical degree from the University of Rochester School of Medicine and Dentistry. He completed his internal medical residency at the Yale University’s Primary Care Residency Program Yale New Haven in 2014.
​
Dr. Moreno is excited to join Yale Internal Medicine Associates. He enjoys working together with patients and developing a plan tailored to their individual needs. He has a special interest in obesity treatment and management of obesity-related conditions. He lives in Madison together with his wife and son. He loves baseball and is a fan of the New York Mets.
Wejahat Mehal
MD, DPhil
Wajahat Mehal MD, DPhil, is Professor of Medicine in Digestive Diseases, and Director of the Yale Fatty Liver Disease Program and the Yale Metabolic Health and Weight Loss Program.
​
He cares for patients with all liver diseases in the outpatient and inpatient setting, and particularly focuses on the areas of non-alcoholic and alcoholic fatty liver disease. He is also trained in obesity medicine and endobariatrics, managing patients by providing the full range of weight loss interventions, which include nutrition, medications, meal replacement, endobariatrics, and referrals to bariatric surgery.
​
In addition, he has an active NIH-funded translational research program in the areas of inflammation and fibrosis.
Katherine Heilpern
MD, FACEP
Dr. Katherine (Kate) Heilpern is an emergency medicine physician, academic leader and healthcare executive who serves as Executive Vice President, Yale New Haven Health and President, Yale New Haven Hospital. In addition, she has responsibility for the Yale New Haven Health system service lines, including neurosciences, orthopedics, heart and vascular, women and children’s and transplant.
​
Dr. Heilpern was recruited from New York-Presbyterian (NYP) where she served as Group Senior VP and COO for the NYP-Weill Cornell Division hospitals, responsible for strategy, hospital operations, quality, finance, crisis mitigation, and capital and strategic clinical planning. She also served as the NYP Chief, Office of Provider Professionalism and Support. The office focused on provider professionalism, team culture and communication and the important intersection with quality, patient and provider safety,
​
Prior Dr. Heilpern was a practicing emergency medicine physician for more than 25 years and held multiple leadership positions at Emory School of Medicine and Emory Healthcare, including an adjunct appointment in the Emory Woodruff School of Nursing. For 12 years, she served as the Ada Lee and Pete Correll Professor and Chair of Emergency Medicine. She also served as the Executive Associate Dean of Faculty and Administrative Affairs and interim Chair of Family and Preventive Medicine. Her academic career focused on leadership and team development, advancement of women in emergency medicine, clinical care delivery to vulnerable populations and the acute presentation and management of emerging infectious diseases.
​
Nationally, Dr. Heilpern has served on a number of standing committees and boards for the National Academy of Medicine. She has held numerous national leadership roles with emergency medicine specialty societies, including President of the Society for Academic Emergency Medicine and executive leadership with the Association of Academic Chairs of Emergency Medicine. She is the recipient of a number of national awards recognizing her contributions in leadership, education, diversity and equity. In the early phase of her career, Dr. Heilpern served as a Medical Officer with the Indian Health Service (Navajo Reservation). She is a proud alumna of the University of Virginia and Emory University School of Medicine, and Professor Emerita, Emory University School of Medicine.
Allen Hsiao
MD, FAAP, FAMIA
Allen Hsiao is Professor of Pediatrics, Biomedical Informatics and Data Science, and of Emergency Medicine at the Yale School of Medicine and serves as the Chief Health Information Officer (CHIO) for the Yale School of Medicine and Yale New Haven Health System. Dr. Hsiao also serves as the Vice Chair Clinical Systems, Biomedical Informatics and Data Science.
​
He received his BA in Biomedical Ethics and MD from Brown University, then completed residency training in Pediatrics at Yale before completing fellowships and board certifications in Pediatric Emergency Medicine and Medical Informatics. He has served on numerous medical informatics-related committees for the Hospital and University, as well as nationally for groups such as the American Academy of Pediatrics, Health Information Management Systems Society, and the National Association of Children’s Hospitals and Related Institutions.
​
Dr. Hsiao has published many articles in the pediatric and healthcare informatics literature and regularly presents nationally and internationally on leveraging informatics and the electronic health record (EHR) to support research, optimize systems, and improve transitions of care. He has also served as primary investigator or co-investigator on several NIH and AHRQ-funded grants examining the ways health information technology can impact and improve healthcare. Dr. Hsiao also co-directs the Informatics Core for Yale’s Clinical Translational Science Award (CTSA) from the National Institutes of Health. In this capacity, he works closely with the Yale Center for Clinical Investigations leadership to equip investigators with the tools and information needed for translational and clinical research. This includes leveraging the industry-leading functionalities of the EHR (Epic) system and the clinical trials management system (OnCore) for investigators and patient focused research, with particular emphasis on expanding clinical trials participation by patients from diverse backgrounds to improve health equity and inclusion in clinical research.
​
As the CHIO, Dr. Hsiao leads the medical and clinical informatics work for the Health System and School of Medicine
Trevor Gunn
PhD
Trevor Gunn is Vice President of International Relations for Medtronic, the world’s largest medical technology company. He is Founder and Chair of the USA Healthcare Alliance. He has been Adjunct Professor at Georgetown University for 32 consecutive years.
Gunn was formerly long-time Director of the Commerce Department’s Business Information Service for the Newly Independent States (BISNIS) the clearinghouse for US Government information for doing business in the former Soviet Union.
​
He has worked with the Chamber of Commerce of Southern Sweden, Dover Elevator Corporation (now ThyssenKrupp), International Executive Service Corps and on the staffs of the former San Francisco Mayor and two U.S. Senators. He is Founder and Chairman of the USA Healthcare Alliance. He sits on the U.S. State Department’s Stakeholder Advisory Board on the OECD Guidelines on Corporate Social Responsibility; is an official Advisor to the Office of the US Trade Representative in the “Industry Trade Advisory” system. Gunn chairs the International Affairs Committee at Medtech Europe, Europe's largest medical technology trade association. Further, he is Chair Emeritus and Board Member of the Executive Council on Diplomacy and is a Founding Advisory Board Member to the Geneva-based World Association of Investment Promotion agencies. He sits on the Board of the Washington Export Council, the Board of Advisers of the Washington International Business Council. Finally, he serves on the Advisory Board of the University of Minnesota, Carlson Business School's, Carlson Global Institute. He sits on the Board of Directors of Global Minnesota.
He received his B.A. from University of San Francisco. He received his Ph.D. in International Relations from the London School of Economics in 1992. Gunn speaks Swedish, French and Russian. Gunn, his wife(Anna) and their three children live in Suburban Maryland.
Laurence Coman
MBA
Laurence Coman is a Cofounder and Chief Operating Officer of Avo, a health tech company that leverages AI to embed clinical evidence into point of care workflows, making clinicians’ lives easier and ensuring patients get the proper care. As a Cofounder/COO, he supports the company’s sales and marketing efforts in addition to leading fundraising, customer success, finance, HR, and legal activities.
In 2020, Laurence graduated from Columbia Business School, where he studied entrepreneurship and healthcare. While at Columbia, Laurence served on the boards of the Healthcare Industry Association and the Health Tech Assembly.
Prior to founding Avo and attending Columbia, Laurence worked as an investor at Vector Capital, a private equity firm focused on the software sector. At Vector, Laurence helped evaluate and acquire software companies, in addition to serving as a Board Observer for two of the firm’s portfolio companies.
Laurence is an avid hip-hop and Mets fan, enjoys gardening, and competes in Ironman triathlons in his free time. He received a BS in Economics at The Wharton School and a BA in International Studies and Hispanic Studies from the University of Pennsylvania.
Megan Ranney
MD, MPH
Dr. Megan L. Ranney is an emergency physician, researcher, and leading advocate for innovative approaches to public health. She is the Dean of the Yale School of Public Health, the C.-E. A. Winslow Professor of Public Health, and a Professor of Emergency Medicine at Yale University. Dr. Ranney is the first Dean to lead the school since its independence in 2024. Under her leadership, the school is pursuing a bold new strategic vision of linking science and society, making public health foundational to communities everywhere. Her first-hand experiences as a member of the Peace Corps and a practicing physician have fueled her commitment to high-quality science.
She is a national leader in restarting the science of firearm injury prevention as a health issue. Her work on violence prevention, the use of technology to augment prevention, and the role of systems-level change in care has been published over 200 times. She is an elected member of the National Academy of Medicine and the Connecticut Academy of Science and Engineering, a Fellow of the American College of Emergency Physicians, and a member of the Aspen Global Leadership Network.
In addition to her scholarly work, she has harnessed social media to spark large public health movements, such as securing and distributing over 17 million units of donated PPE at the peak of the COVID-19 pandemic. She started two successful non-profits and serves as a board member on national and international organizations that work to use science to reduce firearm injury, improve science communication, and enhance emergency care, among other leadership roles. Dr. Ranney has also shaped bipartisan policy and public opinion. She has provided Congressional testimonies and other expertise to the U.S. Surgeon General and the White House across multiple presidential administrations. She is a sought-after media presence, with over 1,000 national and international appearances that translate public health messages and science for the public.
Before her Deanship at Yale, Dr. Ranney was previously the Warren Alpert Endowed Professor of Emergency Medicine, Deputy Dean of the School of Public Health, and Founding Director of the Brown-Lifespan Center for Digital Health at Brown University. Dr. Ranney earned her bachelor's degree in history of science, graduating summa cum laude from Harvard University; her medical doctorate, graduating Alpha Omega Alpha from Columbia University; and her master’s degree in public health from Brown University. She completed her residency in Emergency Medicine and a fellowship in Injury Prevention Research at Brown University.
Amanda Skinner
MSN, MBA
Amanda Skinner, is President and Chief Executive Officer of Planned Parenthood Votes! Connecticut and of Planned Parenthood of Southern New England. Amanda is an experienced health care executive committed to improving health equity and health care access. She's a thought leader on sexual/reproductive healthcare, value-based care, and population health. She is a member of the Planned Parenthood Federation of America Board of Directors. Additionally, she serves on the Boards of Directors of BetterHealth (a PP partnership) and the Universal Health Care Foundation of Connecticut, is a member of The Beryl Institute Standing Committee on Equity and Inclusion, and is a Donaldson Fellow of the Yale School of Management.
She has spent her professional life working to advance equity in health care across health care settings – private practice, consulting, large academic health system, payer, and community-based non-profit provider. Amanda is a certified nurse-midwife and spent 10 years in clinical practice and practice leadership. She is a past chair of the CT Chapter of the American College of Nurse-Midwives and led a successful policy campaign to expand the practice of nurse-midwives in Connecticut. Following her graduation from Yale School of Management, Amanda joined The Chartis Group as a healthcare strategy and operations consultant, spent 6 years at Yale New Haven Health System where she was instrumental in building out the population health, clinical integration, and value-based care operations, and then served as Vice President and General Manager at Optum growing an integrated population health analytics and services business. In 2017 Amanda accepted her dream job at Planned Parenthood of Southern New England. She is a graduate of Rice University, holds a MSN from the Yale School of Nursing with a clinical focus in nurse-midwifery, and an MBA from the Yale School of Management. Amanda lives in Connecticut with her husband, Kalter, and their dogs Butch and Sundance.
Gregg Gonsalves
PhD
Gregg Gonsalves is an Associate Professor (Adjunct) of Law at Yale Law School, the co-director of the Global Health Justice Partnership, and a leading HIV/AIDS activist. Gonsalves is also an Assistant Professor of Epidemiology of Microbial Diseases at Yale School of Public Health. His research focuses on the use of quantitative models for improving the response to epidemic diseases.
For more than 20 years, he worked on HIV/AIDS and other global health issues with several organizations, including the AIDS Coalition to Unleash Power, the Treatment Action Group, Gay Men’s Health Crisis, and the AIDS and Rights Alliance for Southern Africa. He was also a fellow at the Open Society Foundations and in the Department of Global Health and Social Medicine at Harvard Medical School from 2011-2012. He is a 2011 graduate of Yale College and received his PhD from Yale Graduate School of Arts and Sciences/School of Public Health in 2016.
Victoria Veltri
JD, LLM
Victoria Veltri, JD, LLM, is a senior policy fellow with the National Academy for State Health Policy (NASHP), where she serves as policy expert on health care issues related to hospital and health system costs, health care market oversight, delivery and payment reform, primary care, rural health care, and health care litigation. She provides direct technical assistance to states. She was executive director of Malta House of Care, in Hartford, CT, a free clinic providing comprehensive primary care to uninsured residents of greater Hartford.
Prior to serving at Malta House of Care, Veltri was the executive director of Connecticut’s Office of Health Strategy (OHS), overseeing its mission to implement comprehensive, data-driven strategies that promote equal access to high-quality health care, control costs, and ensure better health for Connecticut residents. She led a bipartisan process that implemented Connecticut’s first health care cost growth benchmarks, primary care spending targets, and quality benchmarks. She oversaw the state’s Certificate of Need Program and its All-Payer Claims Database (APCD), and developed with partners the Connecticut Healthcare Affordability Index. Veltri also successfully led the launch of the Connecticut Health Information Exchange, Connie. Veltri was the chief health policy advisor to the lieutenant governor’s office, coordinating the state’s health reform initiatives, including the Health Care Cabinet and the creation of OHS. She was the state's healthcare advocate in the Office of the Healthcare Advocate, where she oversaw the office’s mission to assist consumers select health plans and understand their health care rights, and to pursue systemic healthcare advocacy. Veltri served on the boards of the Connecticut Health Insurance Exchange and Connecticut Partners for Health.
Robert Stavert
MD, MBA, FAAD
Robert Stavert, MD, MBA, FAAD is a physician leader and digital health innovator dedicated to enhancing patient access and experience through technology-driven care. He is the inaugural Medical Director for Digital Patient Experience and Virtual Care at Yale New Haven Health System, where he leads initiatives to expand virtual care and optimize digital health solutions for patients and providers.
​
Dr. Stavert has a deep background in digital health, telemedicine, and healthcare innovation. He co-founded Medumo, a digital health company that delivers customized educational content and reminders to patients via text and email, improving engagement and adherence. As Head of Clinical Affairs, he played a key role in its growth and ultimate acquisition in 2019 by Phillips.. He later joined Science 37, a telemedicine company designed to increase access to clinical trials through decentralized research models.
​
Prior to his digital health leadership roles, Dr. Stavert was Chief of the Division of Dermatology at Cambridge Health Alliance (CHA), where he spearheaded the successful implementation of an eConsult system to enhance specialty care access and clinician collaboration.
Dr. Stavert completed his undergraduate studies at Harvard University and earned his MD and MBA through Yale’s combined School of Medicine and School of Management program. He trained in internal medicine at Beth Israel Deaconess Medical Center in Boston and completed his dermatology residency at Yale.
​
Beyond his work in digital health, Dr. Stavert remains committed to clinical care and health equity. As Director of Community Engagement in Yale’s Department of Dermatology, he provides dermatologic care at Cornell Scott Hill Health Center, focusing on underserved populations. He is also an accomplished educator, having received the Teacher of the Year award in the Harvard Dermatology Residency Program, and serves as a dedicated mentor to students and trainees.
Lee Schwamm
MD
Dr. Lee H. Schwamm, MD is Associate Dean for Digital Strategy and Transformation for Yale School of Medicine, and Senior Vice President + Chief Digital Health Officer for Yale New Haven Health System. In this role, he is leading the development of a new digital health strategy for the school and the health system, and serves as an influential physician leader and an agent of change to catalyze the equitable adoption of virtual care and digital enablement throughout the enterprise.
​
Before joining Yale, Dr. Schwamm spent 3 decades of service at the Mass General Brigham Health System in academic and administrative leadership roles. He was the inaugural C. Miller Fisher Chair in Vascular Neurology, Executive Vice Chair of Neurology and Director of the Center for TeleHealth at Massachusetts General Hospital; Vice President for Digital Patient Experience and Virtual Care, and Chief Digital Advisor for the Mass General Brigham Health System, and a Professor of Neurology at Harvard Medical School. He oversaw all systemwide virtual care and telehealth activities including synchronous and synchronous virtual visits and consults, remote patient monitoring, virtual urgent care and online second opinions. During the first 6 months of COVID, he led adoption efforts for 10,000 clinicians to provide over 1.7 M virtual visits, and introduced a suite of innovative inpatient virtual solutions.
​
A graduate of both Harvard College and Harvard Medical School, he completed residency training in neurology, and fellowship training in stroke and neurocritical care, all at Massachusetts General Hospital where he subsequently joined the faculty in 1996. He has spent the past 2 decades in telehealth, as a pioneer in telestroke and a leading advocate and policy advisor for the American Heart Association. He is a an internationally recognized expert in stroke diagnosis, treatment and prevention and a Fellow of the American Heart Association, American Academy of Neurology and the American Neurological Association. His research has been funded by many organizations including the NIH, AHA, PCORI, AHRQ, HRSA, CDC, and others, and he is the author of >500 peer-reviewed articles and chaired many of the current practice guidelines for stroke and telehealth-enabled care delivery. Under his leadership, the AHA Get with the Guidelines–Stroke Registry has grown into the world’s largest stroke registry with over 8M patient encounters; it has changed stroke practice at hospitals across the US, and set a global standard for stroke care. He has received numerous awards for innovation, leadership, and advocacy in the field of stroke and digital health, and held many senior leadership positions within the AHA, including service on their National Board of Directors. He has served on multiple editorial boards, including the digital health section editor for Stroke, and the international advisory board for Lancet Digital Health.
Nick Culbertson
Nick Culbertson is the Managing Director of Techstars AI Health Baltimore, powered by Johns Hopkins University and CareFirst BlueCross BlueShield. The mission of the Techstars AI Health Baltimore accelerator is to empower AI healthcare startups to achieve rapid commercial traction through mentorship, resources, and network access, accelerating their path to market leadership and sustainable impact.
​
Prior to joining Techstars, Nick co-founded, led, and sold Protenus, a Baltimore-based AI company that brought automation and risk reduction to healthcare compliance. Under Nick's leadership, Protenus was recognized by Gartner as a Cool Vendor in Healthcare Artificial Intelligence, by CB Insights as one of the Most Innovative Digital Health Startups, by Forbes as one of America's Top Startup Employers, and by Modern Healthcare as one of the Best Places to Work in Healthcare.
​
Nick was named one of "Healthcare's Entrepreneurs to Know" by Becker's Hospital Review and was recognized as one of Baltimore's Top 40 under 40 and EY's Entrepreneur of the Year. Nick is a lead contributor to over 20 patents and co-author to several peer-reviewed articles.
​
Prior to co-founding Protenus, Nick served eight years in the U.S. Army as a highly decorated U.S. Special Forces Operator (Green Beret) and Advanced Tactical Practitioner. He holds a B.S. from The Johns Hopkins University and has research experience in the fields of genetics, synthetic biology, metabolic engineering, and medicine. Currently, Nick serves on the executive board of The 6th Branch, a veteran-led community service organization in East Baltimore. Nick is also an active volunteer with several Baltimore initiatives focused on entrepreneurship and innovation in the Baltimore tech community.
Jason Naidich
MD, MBA
Jason Naidich, MD serves as Chief Learning and Innovation Officer of Northwell Health and Associate Dean for Innovation at the Zucker School of Medicine at Hofstra/Northwell. Dr. Naidich champions innovation across the organization and leads the development of novel approaches and solutions that drive transformative improvement in clinical care, efficiency, and outcomes. In the 3D printing and design lab, the innovation team creates prototypes for internal use and potential commercialization. Most recently, the digital innovation team launched Northwell’s AI Hub, a safe and secure site with over a dozen LLMs.
​
Additionally, Dr. Naidich leads Northwell’s corporate university, the Center for Leaning and Innovation (CLI), which provides education and training to over 85,000 team members. CLI is home to the Patient Safety Institute, a state-of-the-art simulation center, and the Bioskills Education Center . During his tenure, CLI has developed new certificate programs to train allied health professionals and will launch the Northwell School of Health Sciences, a NYC public school.
​
Previously, Dr. Naidich served as Senior Vice President and Executive Director of Northwell’s Central Region. In this role, he was responsible for the development of new programs and facilities, as well as the clinical, operational, and financial performance of the region’s hospitals and outpatient programs. ​Prior to this, Dr. Naidich served as SVP and Executive Director of Imaging Services, where he led the development, growth, and integration of inpatient and outpatient radiology across the entire Northwell health system. He continues to serve as Chair of Radiology at the Zucker School of Medicine at Hofstra/Northwell.
​
Dr. Naidich earned his medical degree from Cornell University Medical College. He completed a residency in diagnostic radiology followed by a fellowship in vascular and interventional radiology at New York University Medical Center, and a fellowship in magnetic resonance imaging at Beth Israel-Deaconess Medical Center. He later earned an MBA with a concentration in health care management from Yale University.
Michael Dunne
MD
Until recently Michael Dunne was the Chief Medical Officer and Head of Development at the Bill & Melinda Gates Medical Research Institute, involved in clinical trials in therapeutic areas aligned with the mission of the Gates Foundation. Prior to joining the Institute, Dunne was the founder and chief scientific officer at Iterum Therapeutics, where he led the development and recent FDA approval of the antibiotic sulopenem.
From 2014 to 2015, Dunne was Vice President of Research and Development at Actavis. He previously served as founder and chief medical officer at Durata Therapeutics beginning in 2009, where he was responsible for the development and successful global registration of dalbavancin. Prior to joining Durata, I worked at Pfizer for 17 years, leading the development and registration of several antibacterial, antifungal, antiviral, and HIV therapeutics. IHewas a member of the Scientific Advisory Committee for the Global Alliance for TB Drug Development and a member of the Expert Scientific Advisory Committee for the Medicines for Malaria Venture.
He currently serves on the Board of Directors at Iterum Therapeutics and on the Editorial Review Board of the journal Clinical Infectious Diseases. He is a member of the Scientific Advisory Board for The Singapore-MIT Alliance for Research and Technology and a fellow of the Infectious Diseases Society of America. Dunne earned my M.D. from the State University of New York Health Science Center at Brooklyn and completed my residency in internal medicine and fellowship training in pulmonary medicine and infectious diseases at Yale University.
Reza Yaesoubi
PhD, MSc
Dr. Yaesoubi is a health decision scientist with focus on developing and applying analytical methods to inform decision making in public health and medicine. His expertise is in developing methods to guide decisions when the evidence base and data are shifting too quickly for any static policy or guideline to suffice (e.g., during outbreaks of novel pathogens or spread of antimicrobial-resistant pathogens). Through incorporating computer simulation models, statistical and machine learning methods, and optimization techniques, he has developed mechanisms to combine data and evidence from disparate sources to inform cost-effective decisions in real-time. He has applied these methods to optimize public health responses to the spread of drug-resistant tuberculosis, antimicrobial-resistant gonorrhea, COVID-19, influenza, and meningitis. He is also interested in and contributed to the theoretical and methodological issues in medical decision-making and health care resource allocation.
John Kao
MD, MBA
The Economist called Kao “Mr. Creativity.” He a serial entrepreneur, pianist, former Harvard Business School professor, best-selling author of "Jamming: The Art and Discipline of Business Creativity", and Tony-nominated producer of Broadway theater and feature films. He has BA and MD degrees from Yale and an MBA from Harvard.
Currently he is a Senior Fellow and Lecturer at Yale School of Engineering and Applied Science where he is teaching a new course he developed called “Finding Yourself in the Future of Creativity.” Kao has advised governments, companies and startup entrepreneurs, and is also co-founder and chairman emeritus of ThayerMahan, Inc. a leader in the integration of robotics, advanced sensors, and AI for maritime intelligence.
​
Previously Kao was the Chair of the World Economic Forums's Global Innovation Council. He has advised companies such as BASF, American Express, Bass Brothers Enterprises, and Equinor. Kao is the founder and significant contributor of FarPlay Inc., Million Doors Inc., and Biosurface Technology Inc. From 1982-1996 he was on the faculty of Harvard Business School. Additionally he has be an innovation policy advisor to the governments of Singapore, Finland, Australia, and the United States, among others.
The high point of Kao's musical career was a summer on the road with Frank Zappa and the original Mothers of Invention in 1969.
Malick Diara
MD, MPH, MBA
Diara joined ExxonMobil in 2009 with more than 20 years of experience in international health and development. In 2010, Ihebecame the Corporate Public Health Manager of the Medicine and Occupational Health (MOH) Department. Responsibilities were focused on infectious disease prevention and control in Company workplaces. By 2016, they included oversight of the Company Culture of Health platform. He has been instrumental in Company preparedness and response for COVID-19, as well as for MERS Corona Virus, Ebola, Zika, and outbreaks due to other infectious diseases. In 2023, he was promoted Occupational Health Manager to lead related services for the new Company operations that are being developed in Mozambique.
Prior to ExxonMobil, Diara worked with international health organizations in Washington DC for 9 years and in West Africa for 12 years. With funding from USAID, the French Cooperation or the European Union, and in partnership with local authorities and organizations such as UNICEF and WHO, he supported the design, implementation and evaluation of global, national and local public health programs. He also worked as a physician for two years in Guadeloupe, French West Indies.
Diara is a former member of the Global Health Board of the National Academy of Medicine and CDC Foundation Global Health Threat Round Table while presently being a member of the American Society of Tropical Medicine and Hygiene. He is a physician with a Medical Doctorate from Dakar, Senegal School of Medicine, an MBA from the Paris, Institut Superieur de Gestion and an MPH from Tulane, New Orleans.
Margaret Alabi
ParmD, EMBA
An accomplished professional with a proven track record in the pharmaceutical industry and extensive experience in patient advocacy at Regeneron Pharmaceuticals, Margaret Alabi is driven by a deep passion for improving the lives of people suffering from severe chronic immunologic diseases. She believes in harnessing the power of pharmaceutical innovations and aligning them with patient needs to truly make a difference.
As an ICF-certified coach, Alabi have a unique ability to inspire and motivate, fostering both personal and professional growth and she is committed to fostering growth and excellence in others. Her focus is on developing future leaders - guiding individuals from adolescence into adulthood, and nurturing their development throughout their careers.
She is currently earning my EMBA at Yale School of Management to further refine her managerial acumen and leadership skills. She is particularly interested in the intersection of technology and healthcare and how this convergence can contribute to digital health equity.
Empathy, healthcare innovation, and patient advocacy drive her efforts to create a more inclusive, efficient, and people-centric healthcare future. She looks forward to connecting with like-minded professionals and institutions.
Stephen Knight
MBA, MD
Stephen Knight joined F-Prime Capital in 2003 where he serves as President and Senior Managing Partner. He has worked in the pharmaceutical and biotechnology industries for over 30 years and invests broadly across healthcare. Steve serves on the Board of Directors of Atalanta Therapeutics, Leyden Labs, Paradigm, Quantum Circuits, Inc. (QCI), Skyline Therapeutics, and Xaira Therapeutics. Steve previously served on the boards of several private and public health care companies including Beam Therapeutics (NASDAQ: BEAM), Blueprint Medicines (NASDAQ: BPMC), Denali Therapeutics (NASDAQ: DNLI), FoldRx Pharmaceuticals (acquired by Pfizer), Innovent Biologics (1801.HK), Iora Health (acquired by One Medical), Ironwood Pharmaceuticals (NASDAQ: IRWD), NextWave Pharmaceuticals (acquired by Pfizer), Prime Medicine (NASDAQ: PRME), Respivert, Ltd (acquired by J&J), Sana Biotechnology (NASDAQ: SANA), and Semma Therapeutics (acquired by Vertex).
​
Prior to joining F-Prime Capital, Steve held various senior management roles in private and public biotechnology and consulting companies. He also was a researcher at AT&T Bell Laboratories, the National Institutes of Health, and Yale University. He holds an M.D. from the Yale University School of Medicine, an M.B.A. from the Yale School of Organization and Management and received a B.S. in biology from Columbia University, graduating summa cum laude and Phi Beta Kappa.
Murat Günel
MD, FACS, FAHA, FAANS
Dr. Murat Günel, the Sterling Professor of Neurosurgery and Professor of Neurobiology and Genetics, was appointed Chair of the Department of Neurosurgery at Yale School of Medicine and Chief of Neurosurgery at Yale-New Haven Hospital in 2014. He is the director of the Yale Program in Brain Tumor Research and co-director of the Yale Program on Neurogenetics. Dr. Günel obtained his medical degree at Istanbul University and completed both his internship and residency at Yale-New Haven Hospital. His clinical expertise is in treating complex brain aneurysms and vascular malformations, as well as brain tumors.
​
Dr. Günel’s research interest focuses on gene discovery in diseases of the human brain, including its development, vascular disease and tumors. Among these, the Günel lab has expertise in the application of next generation genomic technologies to study the genetic and epigenetic causes of brain and central nervous system tumors, focusing on meningiomas with various histological and pathological grades. Günel lab integrates multilevel approaches including whole exome and whole genome sequencing, molecular inversion probe sequencing (MIPS), whole genome genotyping, array based gene expression, RNA sequencing, whole genome methylation and chromatin immunoprecipitation sequencing (ChIP-seq), followed by downstream biological studies to comprehensively analyze these tumors. The long-term goal of this approach is to define the molecular make-up of these tumors, which will then guide the development of novel therapies, including oncolytic viruses.
​
In 2015, Dr. Günel was elected to the National Academy of Medicine, the highest distinction in medical sciences. He is a member of the American Association of Neurological Surgeons (AANS) and the Congress of Neurological Surgeons (CNS), both who collectively honored him in 2022 as the fourth recipient of the prestigious Ralph G. Dacey Medal for Outstanding Cerebrovascular Research. In 2021, he received the WINN award, given by the Society of Neurological Surgeons to recognize outstanding, continuous commitment to research in the neurosciences by a neurological surgeon. Dr. Günel previously served as chair of the AANS/CNS Cerebrovascular Section in 2011 and has been elected to the Society of Neurological Surgeons and Academy of Neurological Surgeons. Dr. Günel has been recognized by the Turkish Academy of Arts and Sciences for Outstanding Achievement in Health and Life Sciences and by Kadir Has University for Outstanding Scientific Achievement in Neurosciences.
Reshma Ramachandran
MD, MPP, MHS
Reshma Ramachandran, MD, MPP, MHS is a family physician, health services researcher, and Assistant Professor within the Section of General Internal Medicine in the Department of Medicine at Yale University. She has published several peer-reviewed research articles and commentaries on the realignment of incentives for healthcare stakeholders including pharmaceutical companies, hospitals, and universities towards prioritizing equitable patient access to safe, effective health technologies.
She co-directs the Yale Collaboration for Regulatory Rigor, Integrity, and Transparency (CRRIT), an interdisciplinary initiative aligning research on medical product evaluation, approval, and coverage with the goal of advancing policies that improve patient health and healthcare. She has testified before the U.S. House of Representatives Committee on Energy and Commerce and U.S. Senate Health, Education, Labor, and Pensions Committee.
Previously, Dr. Ramachandran worked as research faculty as part of the Innovation + Design Enabling Access (IDEA) Initiative at the Johns Hopkins Bloomberg School of Public Health. Dr. Ramachandran trained in both medicine at the Alpert Medical School at Brown University and in public policy at the Harvard Kennedy School of Government. She completed her family medicine residency at Kaiser Permanente Los Angeles Medical Center and fellowship training at the National Clinician Scholars Program at Yale University.
Timothy Callaghan
MA, PhD
Timothy Callaghan is an Associate Professor in the Department of Health Law, Policy, and Management at the Boston University School of Public Health. His research focuses on how politics, policy, and place work together to influence health in America.
He has conducted extensive research on individual health attitudes and behaviors, with a particular emphasis on understanding and overcoming vaccine hesitancy. Dr. Callaghan also regularly studies health access and outcomes for vulnerable populations, with a particular emphasis on studying rural health. Dr. Callaghan is also the Co-Director of the newly launched Politics and Health Lab at Boston University.
Akiko Iwasaki
PhD
Akiko Iwasaki, Ph.D. is a Sterling Professor of Immunobiology at the Yale University School of Medicine. Her research focuses on the mechanisms of immune defense against viruses at mucosal surfaces, which are a major site of entry for infectious agents. Professor Iwasaki received her Ph.D. in Immunology from the University of Toronto and completed her postdoctoral training with the National Institutes of Health before joining Yale’s faculty in 2000.
She has been a Howard Hughes Medical Institute Investigator since 2014. Professor Iwasaki has received many awards and honors including Forbes 50 over 50 Innovation 2024, TIME 100 Most Influential People 2024, TIME 100 HEALTH Most Influential People Affecting Global Health 2024, and the Else Kröner Fresenius Prize for Medical Research 2023. She was elected to the National Academy of Sciences in 2018, to the National Academy of Medicine in 2019, to the American Academy of Arts and Sciences in 2021 and was appointed President of American Associations of Immunologists (AAI) in 2023. Professor Iwasaki has been a leading scientific voice during the COVID-19 pandemic and is also well known for her Twitter advocacy on women and underrepresented minorities in the science and medicine fields. She was named to the 2023 STATUS list of the ultimate list of leaders in life sciences.
Professor Iwasaki is the director of the Center for Infection and Immunity and is at the forefront of several long COVID investigations including the Mount-Sinai Yale Long COVID study, Yale LISTEN study, and Yale Paxlovid trial.
Lauren Pischel
MD, MSc
Dr. Lauren Pischel obtained her undergraduate degree in biology at Brown University and worked in the lab of Dr. Jake Kurtis on the development of a pediatric malaria vaccine. She obtained her MD at Stanford where she conducted research with Dr. Julie Parsonnet on the impact of an antimicrobial triclosan on the human microbiome. She then completed her internal medicine residency at Yale where she was awarded the primary care award for the Fair Haven Community Health Center.
She subsequently pursued her clinical and research fellowship in infectious diseases at Yale under the mentorship of Saad B Omer and completed her Master's of Science in the epidemiology of infectious diseases at the Yale School of Public Health. Her research interests include the epidemiology and household transmission of COVID-19 and influenza as well as estimating vaccine effectiveness using real-world data and the epidemiology emerging infectious diseases.
